Correlation between programmed cell death-1 receptor gene polymorphism and sensitivity to platinum-based chemotherapy in gastric cancer

YU Lingling; HE Sumei; ZHAO Wan; XU Wenxin

doi:10.7619/jcmp.20212160

Journal of Clinical Medicine in Practice > 2021 > 25(20): 46-51. > DOI: 10.7619/jcmp.20212160

YU Lingling, HE Sumei, ZHAO Wan, XU Wenxin. Correlation between programmed cell death-1 receptor gene polymorphism and sensitivity to platinum-based chemotherapy in gastric cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(20): 46-51. DOI: 10.7619/jcmp.20212160

Citation:

PDF (870 KB)

Correlation between programmed cell death-1 receptor gene polymorphism and sensitivity to platinum-based chemotherapy in gastric cancer

1.
Suzhou Science and Technology City Hospital Affiliated to Nanjing Medical University, Suzhou, Jiangsu, 215000
2.
Caohu People's Hospital in Xiangcheng District in Suzhou of Jiangsu Province, Suzhou, Jiangsu, 215144

More Information

Received Date: May 23, 2021
Available Online: November 15, 2021
Published Date: October 27, 2021

Graphical Abstract

Abstract

Abstract

Objective To investigate the correlations between rs36084323, rs2227982, rs7421861 polymorphisms of programmed cell death-1 receptor (PD-1) and sensitivity to platinum-based chemotherapy in gastric cancer.
Methods One hundred and three gastric cancer patients were selected as study objects, and given two cycles of oxaliplatin plus tiggio (SOX) or cisplatin, paclitaxel plus 5-fluorouracil (PCF) chemotherapy. After chemotherapy, the patients were divided into sensitive group (45 cases) and resistant group (58 cases) according to RECIST 1.1 version of solid tumor efficacy evaluation criteria(RECIST). After chemotherapy, peripheral venous blood was collected, and the polymorphism of rs36084323, rs2227982 and rs7421861 of PD-1 gene was detected by the TaqMan probe single nucleotide polymorphism (SNP) genotyping technique, and the relationship between the polymorphism and the susceptibility of patients with gastric cancer to platinum chemotherapy was analyzed.
Results The genotype frequency distribution of rs36084323, rs2227982 and rs7421861 of PD-1 gene complied with Hardy-Weinberg equilibrium law (P>0.05). The genotype and allele distribution of PD-1 locus rs2227982 and rs7421861 in the sensitive group and the resistant group showed significant differences(P < 0.05). The sensitive of TT genotype of allele T(OR=1.739, 95%CI, 1.656 to 1.867)and CT genotype(OR=1.524, 95%CI, 1.435 to 1.663)to chemotherapy and were significantly higher than that of CC genotype and C allele (P < 0.05). T allele had higher sensitivity to chemotherapy than C allele (OR=1.721, 95%CI, 1.603 to 1.851), and the difference was statistically significant (P < 0.05). TT genotype (OR=1.605, 95%CI, 1.556 to 1.767) and CT genotype (OR=1.414, 95%CI, 1.372 to 1.525) of rs7421861 had lower sensitivity to chemotherapy than CC genotype, and T allele had lower sensitivity to chemotherapy than C allele (OR=1.531, 95% CI, 1.423 to 1.672), and the differences were statistically significant (P < 0.05). Logistic regression analysis showed that the degree of differentiation, rs2227982 polymorphism and rs7421861 polymorphism of PD-1 gene were significantly correlated with the sensitivity to platinum chemotherapy in gastric cancer patients (P < 0.01).
Conclusion The polymorphism of rs2227982 and rs7421861 locus of PD-1 gene may be related to the sensitivity of patients with gastric cancer to platinum chemotherapy, and the individuals carrying the T allele of rs2227982 have better response to platinum chemotherapy, and the individuals carrying the C allele of rs7421861 have poor response to platinum chemotherapy.
- programmed cell death-1 receptor,
- multinucleotides,
- polymorphism,
- gastric cancer,
- chemotherapy,
- sensitivity

FullText(HTML)

References (22)

References

[1]	KARIMI P, ISLAMI F, ANANDASABAPATHY S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(5): 700-713. doi: 10.1158/1055-9965.EPI-13-1057
[2]	王少明, 郑荣寿, 张思维, 等. 2015年中国胃癌流行特征分析[J]. 中华流行病学杂志, 2019, 40(12): 1517-1521. doi: 10.3760/cma.j.issn.0254-6450.2019.12.003
[3]	张亚娟, 常德, 张健鹏. 肺癌化疗中铂类耐药的研究进展[J]. 中国医学科学院学报, 2017, 39(1): 150-155. doi: 10.3881/j.issn.1000-503X.2017.01.025
[4]	郑艺, 尹继业, 周宏灏, 等. 基因多态性与铂类药物毒性反应研究进展[J]. 中国临床药理学与治疗学, 2014, 19(9): 1051-1056. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL201409020.htm
[5]	TANG N, LYU D, ZHANG Y, et al. Association between the ERCC₁ polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis[J]. BMC Womens Health, 2017, 17(1): 43. doi: 10.1186/s12905-017-0393-z
[6]	LIBLAB S, VUSURATANA A, AREEPIUM N. ERCC1, XRCC1, and GSTP1 polymorphisms and treatment outcomes of advanced epithelial ovarian cancer patients treated with platinum-based chemotherapy[J]. Asian Pac J Cancer Prev, 2020, 21(7): 1925-1929. doi: 10.31557/APJCP.2020.21.7.1925
[7]	TIBALDI C, LUNGHI A, BALDINI E. Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors[J]. World J Clin Oncol, 2017, 8(4): 320-328. doi: 10.5306/wjco.v8.i4.320
[8]	WU Y, CAO D, QU L, et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer[J]. Oncotarget, 2017, 8(38): 64066-64082. doi: 10.18632/oncotarget.19318
[9]	TANG W, CHEN S, CHEN Y, et al. Programmed death-1 polymorphisms is associated with risk of esophagogastric junction adenocarcinoma in the Chinese Han population: a case-control study involving 2, 740 subjects[J]. Oncotarget, 2017, 8(24): 39198-39208. doi: 10.18632/oncotarget.17338
[10]	EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1)[J]. Eur J Cancer, 2009, 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026
[11]	谢晓燕, 李超, 敬梅, 等. ERCC2 Asp312Asn/Lys751Gln基因多态性与晚期非小细胞肺癌铂类药物化疗敏感性相关性的临床观察[J]. 临床和实验医学杂志, 2019, 18(20): 2190-2193. doi: 10.3969/j.issn.1671-4695.2019.20.018
[12]	PITT J M, VÉTIZOU M, DAILLōRE R, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors[J]. Immunity, 2016, 44(6): 1255-1269. doi: 10.1016/j.immuni.2016.06.001
[13]	BAI J, GAO Z, LI X, et al. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade[J]. Oncotarget, 2017, 8(66): 110693-110707. doi: 10.18632/oncotarget.22690
[14]	XIA L, LIU Y, WANG Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions[J]. Oncologist, 2019, 24(suppl 1): S31-S41.
[15]	毛璐, 鞠侯雨, 任国欣. 程序性细胞死亡受体-1与其配体信号通路的调控及其在头颈鳞状细胞癌治疗中的研究进展[J]. 国际口腔医学杂志, 2018, 45(5): 560-565. https://www.cnki.com.cn/Article/CJFDTOTAL-GWKQ201805014.htm
[16]	WANG X, GUO G, GUAN H, et al. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 87. doi: 10.1186/s13046-019-1085-3
[17]	LV J W, LI J Y, LUO L N, et al. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials[J]. J Immunother Cancer, 2019, 7(1): 159. doi: 10.1186/s40425-019-0636-7
[18]	XU J, ZHANG Y, JIA R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2): 515-523. doi: 10.1158/1078-0432.CCR-18-2484
[19]	REN H T, LI Y M, WANG X J, et al. PD-1 rs2227982 polymorphism is associated with the decreased risk of breast cancer in northwest Chinese women: a hospital-based observational study[J]. Medicine: Baltimore, 2016, 95(21): e3760. doi: 10.1097/MD.0000000000003760
[20]	HASHEMI M, KARAMI S, SARABANDI S, et al. Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies[J]. Cancers (Basel), 2019, 11(8): 1150. doi: 10.3390/cancers11081150
[21]	ZANG B, CHEN C, ZHAO J Q. PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population[J]. Aging: Albany NY, 2020, 12(4): 3771-3790.
[22]	赵万, 奉林, 余玲玲, 等. PD1多态性与晚期非小细胞肺癌铂类化疗敏感性及骨髓抑制的关系[J]. 肿瘤预防与治疗, 2020, 33(8): 651-657. doi: 10.3969/j.issn.1674-0904.2020.08.004

Cited By

Get Citation

PDF

XML

Article views (225) PDF downloads (15)

Turn off MathJax

Article Contents

Abstract

References

Correlation between programmed cell death-1 receptor gene polymorphism and sensitivity to platinum-based chemotherapy in gastric cancer

Abstract

References

Catalog

Export File

Citation

Format

Content